Carlos Grande

4.4k total citations
82 papers, 1.4k citations indexed

About

Carlos Grande is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Carlos Grande has authored 82 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 23 papers in Genetics. Recurrent topics in Carlos Grande's work include Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (12 papers). Carlos Grande is often cited by papers focused on Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (23 papers) and CAR-T cell therapy research (12 papers). Carlos Grande collaborates with scholars based in Spain, United States and France. Carlos Grande's co-authors include Albert Oriol, Josep‐María Ribera, Mar Tormo, Jesús María Hernández‐Rivas, Concepción Bethencourt, Eloy del Potro, Evarist Feliú, Pilar Bastida, J. Casal and Salut Brunet and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Carlos Grande

73 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carlos Grande Spain	18	622	504	426	371	207	82	1.4k
Atsushi Kikuta Japan	21	596 1.0×	256 0.5×	228 0.5×	654 1.8×	215 1.0×	118	1.5k
AH Goldstone United Kingdom	22	567 0.9×	441 0.9×	303 0.7×	808 2.2×	68 0.3×	50	1.5k
Paul G. Schlegel Germany	23	600 1.0×	170 0.3×	331 0.8×	490 1.3×	136 0.7×	56	1.8k
Joseph M. Wiley United States	19	338 0.5×	168 0.3×	262 0.6×	630 1.7×	264 1.3×	37	1.5k
Noga Shem‐Tov Israel	23	584 0.9×	241 0.5×	409 1.0×	1.0k 2.8×	63 0.3×	85	1.7k
Atsushi Makimoto Japan	22	478 0.8×	179 0.4×	157 0.4×	619 1.7×	172 0.8×	91	1.5k
Keiko Yumura‐Yagi Japan	18	332 0.5×	243 0.5×	383 0.9×	605 1.6×	150 0.7×	49	1.2k
K Kawa Japan	21	715 1.1×	506 1.0×	221 0.5×	677 1.8×	81 0.4×	51	1.6k
Sandra H. Thomas United States	25	978 1.6×	471 0.9×	140 0.3×	386 1.0×	64 0.3×	60	1.9k
Gero Massenkeil Germany	24	667 1.1×	193 0.4×	297 0.7×	649 1.7×	89 0.4×	56	1.9k

Countries citing papers authored by Carlos Grande

Since Specialization

Citations

This map shows the geographic impact of Carlos Grande's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Grande with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Grande more than expected).

Fields of papers citing papers by Carlos Grande

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Grande. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Grande. The network helps show where Carlos Grande may publish in the future.

Co-authorship network of co-authors of Carlos Grande

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Grande. A scholar is included among the top collaborators of Carlos Grande based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Grande. Carlos Grande is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oliveira, Ana Carla, Tycho Baumann, Carlos Grande, et al.. (2025). Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma. Cancers. 17(7). 1065–1065.

Morata, Jordi, Raúl Tonda, Carlos Grande, et al.. (2025). Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma. PLoS ONE. 20(3). e0318689–e0318689.

Villasboas, José C., Stephen D. Smith, Carlos Grande, et al.. (2024). Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY).. Journal of Clinical Oncology. 42(16_suppl). 7058–7058. 1 indexed citations

Grande, Carlos, Antonio Gutiérrez, Ángel Ramírez Páyer, et al.. (2024). Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group. Clinical Cancer Research. 30(17). 3704–3714.

Martı́n, Alejandro, Mónica Baile, Guillermo Rodríguez‐Domínguez, et al.. (2023). Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO. British Journal of Haematology. 203(2). 202–211.

Martín‐Sánchez, Esperanza, Aintzane Zabaleta, Catarina Maia, et al.. (2023). Deep Characterization of Immune Dysfunction in Patients with Multiple Myeloma (MM) and Identification of Cellular Biomarkers for Tailored Vaccination Strategies. Blood. 142(Supplement 1). 643–643.

Vallès, Ermengol, Jesús Jiménez, Julio Martí‐Almor, et al.. (2022). Cryoballoon Ablation for Persistent and Paroxysmal Atrial Fibrillation: Procedural Differences and Results from the Spanish Registry (RECABA). Journal of Clinical Medicine. 11(5). 1166–1166. 2 indexed citations

Sancho, Juan‐Manuel, Rubén Fernández-Álvarez, Carlos Grande, et al.. (2021). R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Medicine. 10(4). 1314–1326. 19 indexed citations

Cerio, Ascensión López-Dı́az de, Ricardo Garcı́a-Muñoz, Ángel Panizo, et al.. (2020). Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression. British Journal of Haematology. 189(6). 1064–1073. 5 indexed citations

10.

Forero‐Castro, Maribel, Cristina Robledo, Eva Lumbreras, et al.. (2015). The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose‐intensive chemotherapy including rituximab. British Journal of Haematology. 172(3). 428–438. 16 indexed citations

11.

Peñalver, Francisco Javier, Julio Delgado, Javier Loscertales, et al.. (2015). Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. European Journal Of Haematology. 96(5). 532–540. 1 indexed citations

12.

Garcı́a-Muñoz, Ricardo, Ángel Panizo, Pilar Giraldo, et al.. (2015). Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity. Immunologic Research. 64(2). 548–557. 11 indexed citations

13.

Grande, Carlos, et al.. (2014). [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia].. PubMed. 37(3). 182–91.

14.

Sáez, Ana I., Mónica García‐Cosío, Antonio José Sáez-Castillo, et al.. (2009). Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma. Leukemia & lymphoma. 50(4). 571–581. 8 indexed citations

15.

Robledo, Cristina, Juan Luis Garcı́a, Dolores Caballero, et al.. (2009). Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B‐cell lymphomas. Cancer. 115(16). 3728–3737. 24 indexed citations

16.

Martínez‐González, Miguel Ángel, et al.. (2008). Linfoma hepático primario: Evolución favorable con quimioterapia combinada con rituximab. Revista Española de Enfermedades Digestivas. 100(11). 724–8. 11 indexed citations

17.

Bernardo, Iván, et al.. (2006). A new HLA‐B allele, HLA‐B*4068, identified in an Equatorian individual†. Tissue Antigens. 68(6). 528–530. 5 indexed citations

18.

Carreras, Francesc, Sandra Pujadas, Rubén Leta, et al.. (2005). Utilidad clínica de la cardiorresonancia magnética para el diagnóstico de pacientes con sospecha de displasia arritmogénica ventricular derecha. Revista Española de Cardiología. 58(9). 1022–1028. 1 indexed citations

19.

Lahuerta, Juan José, Carlos Grande, Joaquín Martínez‐López, et al.. (2003). Tandem transplants with different high‐dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial. British Journal of Haematology. 120(2). 296–303. 30 indexed citations

20.

Grande, Carlos, et al.. (2001). Nasolacrimal Polyurethane Stent Placement for Epiphora: Technical Long-term Results. Journal of Vascular and Interventional Radiology. 12(1). 67–71. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact